Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
Bedard PL, Jhaveri KL, Accordino MK, Cervantes PA, Gambardella V, Hamilton E, Italiano PA, Kalinsky PK, Krop PIE, Oliveira M, Schmid PP, Saura C, Turner PN, Varga A, Cheeti S, Dey A, Hilz S, Hutchinson KE, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Aimi J, Song K, Juric D.
Bedard PL, et al. Among authors: krop pie.
Eur J Cancer. 2025 May 15;221:115397. doi: 10.1016/j.ejca.2025.115397. Epub 2025 Mar 30.
Eur J Cancer. 2025.
PMID: 40203765
Free article.
Clinical Trial.